Edgewise Therapeutics, Inc.
Company Information
Industry Pharmaceutical Preparations
SIC Code 2834
Entity Type operating
SEC Category Large accelerated filer
State of Incorporation DE
Business Address 1715 38TH ST, BOULDER, CO, 80301
Mailing Address 1715 38TH ST, BOULDER, CO, 80301
Phone 720-262-7002
Fiscal Year End 1231
EIN 821725586
Financial Overview
FY2024
-$100.16M
Net Income
$486.82M
Total Assets
$27.60M
Total Liabilities
$346.72M
Stockholders' Equity
$86.10M
Cash & Equivalents
Recent SEC Filings
| Form Type | Date Filed | Document |
|---|---|---|
| 4 Insider stock transaction report | January 23, 2026 | View on SEC |
| 4 Insider stock transaction report | January 5, 2026 | View on SEC |
| 4 Insider stock transaction report | November 24, 2025 | View on SEC |
| 3 Initial insider ownership report | November 24, 2025 | View on SEC |
| 8-K Current report of material events | November 20, 2025 | View on SEC |
| SCHEDULE 13G/A Passive ownership amendment | November 14, 2025 | View on SEC |
| SCHEDULE 13G/A Passive ownership amendment | November 14, 2025 | View on SEC |
| 4 Insider stock transaction report | November 13, 2025 | View on SEC |
| 4 Insider stock transaction report | November 13, 2025 | View on SEC |
| 3 Initial insider ownership report | November 13, 2025 | View on SEC |
Insider Trading
STRONG SELL 1 insiders
5 recent transactions
View Full Insider Trading Profile
Related Companies
Companies in the same industry (SIC: 2834)
Investor Resources
Learn more about SEC filings and how to research public companies.
What is the SEC?
A plain English guide to the Securities and Exchange Commission
Understanding SEC Filings & CIK
How to navigate SEC filings and Central Index Keys
10-K Annual Reports Explained
Everything you need to know about annual reports
S-1 & F-1 IPO Filings
Understanding IPO registration statements
SEC EDGAR Database Guide
How to use the SEC's free filing database
Important Disclaimer
This AI-generated analysis is for informational purposes only and does not constitute financial or investment advice. Always consult with qualified professionals and conduct your own research before making investment decisions.